Alpine Immune Sciences Inc (NASDAQ: ALPN) is 92.08% higher on its value in year-to-date trading and has touched a low of $6.39 and a high of $39.27 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ALPN stock was last observed hovering at around $36.45 in the last trading session, with the day’s gains setting it 0.16%.
Currently trading at $36.61, the stock is 7.48% and 34.57% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.87 million and changing 0.44% at the moment leaves the stock 124.62% off its SMA200. ALPN registered 393.40% gain for a year compared to 6-month gain of 198.13%. The firm has a 50-day simple moving average (SMA 50) of $71.91 and a 200-day simple moving average (SMA200) of -$39.76.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 20.51% loss in the last 1 month and extending the period to 3 months gives it a 111.86%, and is -5.03% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.82% over the week and 5.23% over the month.
Alpine Immune Sciences Inc (ALPN) has around 126 employees, a market worth around $2.40B and $30.80M in sales. Profit margin for the company is -185.10%. Distance from 52-week low is 472.48% and -6.77% from its 52-week high. The company has generated returns on investments over the last 12 months (-33.35%).
Alpine Immune Sciences Inc quarterly earnings per share for the current quarter are estimated at -$0.34 with sales reaching $9.1M over the same period.The EPS is expected to grow by 37.14% this year, but quarterly earnings will post 18.80% year-over-year. Quarterly sales are estimated to grow 227.80% in year-over-year returns.
183 institutions hold shares in Alpine Immune Sciences Inc (ALPN), with institutional investors hold 95.65% of the company’s shares. The shares outstanding are 65.54M, and float is at 47.04M with Short Float at 9.41%. Institutions hold 91.22% of the Float.
The top institutional shareholder in the company is Decheng Capital Management III (Cayman), LLC with over 6.71 million shares valued at $68.96 million. The investor’s holdings represent 13.63% of the ALPN Shares outstanding. As of Jun 29, 2023, the second largest holder is RA Capital Management, L.P. with 4.69 million shares valued at $48.23 million to account for 9.53% of the shares outstanding. The other top investors are Orbimed Advisors LLC. which holds 4.08 million shares representing 8.30% and valued at over $41.96 million, while Great Point Partners LLC holds 6.84% of the shares totaling 3.36 million with a market value of $34.58 million.
Alpine Immune Sciences Inc (ALPN) Insider Activity
The most recent transaction is an insider sale by Rickey James Paul, the company’s. SEC filings show that Rickey James Paul sold 117,764 shares of the company’s common stock on Jan 26 ’24 at a price of $23.32 per share for a total of $2.75 million. Following the sale, the insider now owns 0.0 shares.
Alpine Immune Sciences Inc disclosed in a document filed with the SEC on Jan 25 ’24 that Rickey James Paul () sold a total of 236 shares of the company’s common stock. The trade occurred on Jan 25 ’24 and was made at $22.00 per share for $5192.0. Following the transaction, the insider now directly holds 0.0 shares of the ALPN stock.
Still, SEC filings show that on Dec 28 ’23, ORBIMED ADVISORS LLC (Director) disposed off 1,364,849 shares at an average price of $18.35 for $25.05 million. The insider now directly holds 264,315 shares of Alpine Immune Sciences Inc (ALPN).
